A. Advances in the development of personalized neoantigen- based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215 –229 (2021). 9. Sette, A. et al. The relationship between class I binding af ﬁnity and immuno- genicity of potential cytotoxic T cell epitopes. J. Immunol. 153, 5586 –5592 (1994). 10. Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by con- current motif deconvolution and integration of MS MHC eluted ligand data.Nucleic Acids Res. 48, W449 –W454 (2020).S.H. Kim et al. 1470 Experimental & Molecular Medicine (2024) 56:1461 – 1471 11. O ’Donnell, T. J., Rubinsteyn, A.